Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International

11/16/2021 | 03:46am EST

Biovica’s DiviTum(R)TKa Results Published in Journal of Medical Economics

UPPSALA, SWEDEN / ACCESSWIRE / November 16, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)

Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model's results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.

Care for metastatic breast cancer patients is a large burden on healthcare systems due to cost of therapies, cost of monitoring tests, and management of side effects. The results from this study show that adding DiviTumTKa to care could give a net reduction in costs of up to three times the spend on the new test. The savings come from a decrease in the usage of other monitoring tools such as CT scans and bone scans, and from shortening the amount of time a patient receives expensive medical treatments that ultimately prove to be ineffective.

"Our analysis showed that inclusion of DiviTum®TKa could reduce use of a substantial proportion of traditional monitoring. If use of DiviTum®TKa can also predict lack of benefit from costly CDK4/6i therapy and clinicians then act on that information in a timely fashion, our model suggests that this will result in substantial cost savings to patients and health plans," said Scott D. Ramsey from the Fred Hutchison Cancer Research Center.

"This analysis reinforces our belief that DiviTum®TKa will improve the lives of patients and reduce costs in healthcare. From discussions with patients, we also know that they prefer a regular blood test as a better option than current monitoring practices." said Anders Rylander, CEO of Biovica.

The study publication is included in the November 2021 issue of the Journal of Medical Economics https://doi.org/10.1080/13696998.2021.2003674

Contact

Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com

Biovica - Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .

Attachments

Biovica's DiviTum®TKa results published in Journal of Medical Economics

SOURCE: Biovica International



View source version on accesswire.com:
https://www.accesswire.com/673068/Biovicas-DiviTumRTKa-Results-Published-in-Journal-of-Medical-Economics

n

© Ritzau Denmark, source Ritzau English Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
2021Biovica International
AQ
2021Q2 Interim report - Promising results published at ESMO
AQ
2021Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
CI
2021Biovica International AB Provides Earnings Guidance for the Full Year 2021
CI
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
2021Biovica International
AQ
2021Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
2021Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
2021Biovica International
AQ
More news
Financials
Sales 2022 39,0 M 4,24 M 4,24 M
Net income 2022 -28,0 M -3,04 M -3,04 M
Net cash 2022 110 M 12,0 M 12,0 M
P/E ratio 2022 -38,9x
Yield 2022 -
Capitalization 1 097 M 120 M 119 M
EV / Sales 2022 25,3x
EV / Sales 2023 5,33x
Nbr of Employees 24
Free-Float -
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 38,55 SEK
Average target price 103,00 SEK
Spread / Average Target 167%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOVICA INTERNATIONAL AB (PUBL)-6.88%120
EXACT SCIENCES CORPORATION-2.31%13 101
GUARDANT HEALTH, INC.-27.26%7 395
BGI GENOMICS CO., LTD.3.13%5 854
INVITAE CORPORATION-25.02%2 592
SEEGENE, INC.-2.46%2 581